Adiponectin enhances insulin sensitivity, so blocking its receptors (AdipoRs) could reduce insulin sensitivity, potentially contributing to insulin resistance and increasing the risk of type 2 diabetes. Here, ADIPOQ is linked to type 2 diabetes mellitus.